Navigation Links
Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery
Date:11/16/2010

with prasugrel produced a statistically significant 18 percent reduction in the relative risk of the combined measure of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with clopidogrel in people with chest pain at rest or milder heart attacks (UA/NSTEMI) and a 21 percent reduction in the combined endpoint in people with more severe heart attacks (STEMI). In TRITON-TIMI 38, patients treated with prasugrel also experienced a 50 percent relative risk reduction in stent-related clots when compared with clopidogrel, regardless of stent type.  Additionally, a retrospective analysis of TRITON-TIMI 38 showed that treatment with prasugrel resulted in a 26 percent reduction in the primary endpoint of cardiovascular death, myocardial infarction or stroke compared with clopidogrel among patients aged 75 years or younger who weighed at least 60 kg and had no known history of stroke or TIA.(6)

In the TRITON-TIMI 38 trial, the risk of non-coronary artery bypass graft (non-CABG) major bleeding, including fatal bleeding, was higher with prasugrel (2.2 percent incidence) compared with clopidogrel (1.7 percent incidence).(4,5) Compared with the overall study population, a higher risk of serious bleeding among prasugrel patients was most evident in three distinct patient populations that are readily identifiable: patients who weighed less than 60 kg, patients who were 75 years of age or older and patients who have had a prior transient ischemic attack (TIA) or stroke. A 5 mg maintenance dose is recommended for patients who weigh less than 60 kg. Prasugrel is generally not recommended for use in patients 75 years or older. If treatment is deemed necessary, a 5 mg dose of prasugrel may be used after careful risk-benefit evaluation. Patients with prior TIA or stroke should not be treated with prasugrel.  

About Prasugrel

Daiichi Sankyo Company, Limited, and Eli Lilly and Company co-developed prasugrel, an oral antiplatelet
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
2. Robotic Prostatectomy Expert Dr. David Samadi Talks About Big Strides in the Fight Against Prostate Cancer - Mortality Rate Declines 45%
3. Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
4. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
5. Increased Mortality Associated With Nocturia
6. Unemployment, Health Care Spending Affect Mortality
7. Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
8. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
9. Study Shows Use of AdvanDxs PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
10. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
11. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 29, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, is committed to pursuing ... developed an innovative, patent-pending dual carrier transdermal delivery ... pharmaceutical active ingredients to penetrate the skin and ... The transdermal delivery method also overcomes microbial drug ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli ... details of its long-standing technology transfer program to increase ... Begun in 2003, the effort included Lilly donating manufacturing ... in China , India ... South Africa – all MDR-TB ,hot ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/29/2014)... study has found that certain prostate cancer medications are ... causes in men with congestive heart failure or prior ... findings will help doctors and patients weigh the benefits ... therapy (ADT), which reduces levels of male hormones in ... is a mainstay of treatment for prostate cancer. Despite ...
(Date:10/28/2014)... 27, 2014)—Although oral hormonal therapy is known to ... hormone receptor–positive tumors, about one-half of patients fail ... by Columbia University Medical Center (CUMC) researchers has ... (the most common type of hormone therapy), which ... increased treatment adherence by 50 percent. , The ...
(Date:10/27/2014)... for informal caregiving of elderly people by friends and ... a year, according to a new RAND Corporation study. ... minimum wage would cost $221 billion, while replacing ... annually. , The study, published online by the ... the value of informal caregiving by making use of ...
(Date:10/27/2014)... adopt a new therapy by watching others use it, ... , New technology is like an influential colleague -- ... reminded every five to seven days , CHICAGO ... when they are persuaded to do so by an influential ... adopting innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 CALNOC, ... announced its annual CALNOC Performance Excellence Awards recognizing ... of reducing hospital acquired pressure ulcers, injuries from ... their commitment and dedication to nursing quality. , ... and affiliation. These hospitals have a long and ...
Breaking Medicine News(10 mins):Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 2Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 4
... Texas, Dec. 17 ULURU Inc. (Amex:,ULU) today ... Allowance from the,United States Patent and Trademark Office ... the underlying science behind the Company,s,nanoparticle aggregate technology; ... patent portfolio., Commenting on the issuance of ...
... 17 CSG/SportsCoatings,today announced a major deal ... and FabricAide(TM), to 25 high schools in,Virginia,s ... School District is the model for how ... steps towards minimizing prevalent,bacterial issues like staph ...
... acute and recurrent chronic pain are the leading causes of ... low as 2 percent when these soldiers are treated outside ... percent when troops and officers are treated and managed for ... for therapy, according to a new study from a Johns ...
... Researchers at Oregon Health & Science University have ... a study that suggests new strategies may be in ... The research is published in the current edition of ... The research focused on an important component of the ...
... cardiac safety, TAMPA, Fla., Dec. 17 ... in electro-stun technology, today,announced a major research university ... Systems, S-200 projectile stun gun. Details of the,study ... meeting and/or,in a scientific journal. However, this study ...
... Available Today, Offers Great ... and Now Even More Heart Benefits, HORSHAM, ... -- and then bulge -- from holiday parties ... availability of,NutriSystem Advanced, the company,s breakthrough weight-loss, health ...
Cached Medicine News:Health News:ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent 2Health News:Virginia School District Gets Proactive Against MRSA 2Health News:Pain treatment in the field: Good for soldiers' comfort and better for rebuilding troop strength 2Health News:OHSU research suggests new strategy for protecting aging Americans against infectious disease 2Health News:Medical Study of Stinger S-200 Stun Gun Completed 2Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 2Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 3Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 4
... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus sweatband....
Medicine Products: